Matches in SemOpenAlex for { <https://semopenalex.org/work/W2416236418> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W2416236418 endingPage "A570" @default.
- W2416236418 startingPage "A570" @default.
- W2416236418 abstract "Mature products (MPs - marketed for 10 years or more) are widely used off label (from 15 to 35% according to studies) despite little evidence on benefit risk ratio. This exposes patients to risks or lack of efficacy and healthcare providers to liability. However manufacturers are rarely investing in R&D development for MPs. Indeed MPs face price cuts in Europe, whether due to generic competition, price negotiations or inclusion in reference price groups. Moreover new indications, even if demonstrating a higher value of the drug, often lead to price reductions in Europe due to a combination of price/volume agreements and external reference pricing. Products are included in reference price groups even for a new indication. While reference price groups only include off-patent drugs in France and Italy, these groups may include patented drugs in Spain (if older than 10 years) and Germany.There are significant disincentives for manufacturers to invest in R&D for MPs, preferring instead to develop new molecular entities rather than unlocking the full therapeutic potential of MPs. This is especially the case for small populations (rare and ultra-rare diseases) where there is high unmet medical need and MPs could offer cost-effective solutions with known safety profiles. The development of new indications for MPs can be a win-win solution for patients and payers. It offers an alternative to off label or lengthy and expensive development of new therapies, as well as more equity in patients’ access to treatment. As safety accounts for approximately 30% of drug failures in clinical trials, mature products can also offer a quicker and less expensive access to therapy, especially in areas of high unmet need. Incentives for orphan drugs or pediatric indications have proven to be effective in promoting R&D. New incentives should be developed to promote R&D in MPs." @default.
- W2416236418 created "2016-06-24" @default.
- W2416236418 creator A5021893934 @default.
- W2416236418 creator A5022487279 @default.
- W2416236418 creator A5030408734 @default.
- W2416236418 creator A5032716531 @default.
- W2416236418 creator A5055616921 @default.
- W2416236418 creator A5061805364 @default.
- W2416236418 creator A5084044758 @default.
- W2416236418 date "2015-11-01" @default.
- W2416236418 modified "2023-09-28" @default.
- W2416236418 title "Extension of Indication With Mature Products: Toward More Incentives Rewarding Innovation?" @default.
- W2416236418 doi "https://doi.org/10.1016/j.jval.2015.09.1877" @default.
- W2416236418 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26533201" @default.
- W2416236418 hasPublicationYear "2015" @default.
- W2416236418 type Work @default.
- W2416236418 sameAs 2416236418 @default.
- W2416236418 citedByCount "1" @default.
- W2416236418 countsByYear W24162364182023 @default.
- W2416236418 crossrefType "journal-article" @default.
- W2416236418 hasAuthorship W2416236418A5021893934 @default.
- W2416236418 hasAuthorship W2416236418A5022487279 @default.
- W2416236418 hasAuthorship W2416236418A5030408734 @default.
- W2416236418 hasAuthorship W2416236418A5032716531 @default.
- W2416236418 hasAuthorship W2416236418A5055616921 @default.
- W2416236418 hasAuthorship W2416236418A5061805364 @default.
- W2416236418 hasAuthorship W2416236418A5084044758 @default.
- W2416236418 hasBestOaLocation W24162364181 @default.
- W2416236418 hasConcept C144133560 @default.
- W2416236418 hasConcept C162324750 @default.
- W2416236418 hasConcept C162853370 @default.
- W2416236418 hasConcept C175444787 @default.
- W2416236418 hasConcept C199360897 @default.
- W2416236418 hasConcept C2778029271 @default.
- W2416236418 hasConcept C29122968 @default.
- W2416236418 hasConcept C40700 @default.
- W2416236418 hasConcept C41008148 @default.
- W2416236418 hasConceptScore W2416236418C144133560 @default.
- W2416236418 hasConceptScore W2416236418C162324750 @default.
- W2416236418 hasConceptScore W2416236418C162853370 @default.
- W2416236418 hasConceptScore W2416236418C175444787 @default.
- W2416236418 hasConceptScore W2416236418C199360897 @default.
- W2416236418 hasConceptScore W2416236418C2778029271 @default.
- W2416236418 hasConceptScore W2416236418C29122968 @default.
- W2416236418 hasConceptScore W2416236418C40700 @default.
- W2416236418 hasConceptScore W2416236418C41008148 @default.
- W2416236418 hasIssue "7" @default.
- W2416236418 hasLocation W24162364181 @default.
- W2416236418 hasOpenAccess W2416236418 @default.
- W2416236418 hasPrimaryLocation W24162364181 @default.
- W2416236418 hasRelatedWork W2056010914 @default.
- W2416236418 hasRelatedWork W2099389399 @default.
- W2416236418 hasRelatedWork W2117912286 @default.
- W2416236418 hasRelatedWork W2170451693 @default.
- W2416236418 hasRelatedWork W2358389650 @default.
- W2416236418 hasRelatedWork W2367845749 @default.
- W2416236418 hasRelatedWork W2389739755 @default.
- W2416236418 hasRelatedWork W2797390743 @default.
- W2416236418 hasRelatedWork W3037100507 @default.
- W2416236418 hasRelatedWork W3126066583 @default.
- W2416236418 hasVolume "18" @default.
- W2416236418 isParatext "false" @default.
- W2416236418 isRetracted "false" @default.
- W2416236418 magId "2416236418" @default.
- W2416236418 workType "article" @default.